← All indications
Hearing Loss
A general term for the complete or partial loss of the ability to hear from one or both ears.
Subtype terms (10)
More specific conditions that are subtypes of Hearing Loss in the MeSH hierarchy.
- Deafness
7 drugs (2 approved, 5 experimental)
- Hearing Loss, Bilateral
- Hearing Loss, Conductive
1 drug approved
- Hearing Loss, Functional
- Hearing Loss, Hidden
- Hearing Loss, High-Frequency
- Hearing Loss, Mixed Conductive-Sensorineural
- Hearing Loss, Sensorineural
46 drugs (25 approved, 21 experimental)
- Hearing Loss, Sudden
15 drugs (9 approved, 6 experimental)
- Hearing Loss, Unilateral
Drugs by status
Phase 4 trials (4)
Phase 3 trials (5)
Phase 2 trials (15)
Phase 1 trials (7)
Organizations
Organization Involved with Phase 4 Indications (10)
Organization Involved with Phase 3 Indications (16)
- Genentech
- Auris Medical
- MetArmor
- Sensorion
- National Institute on Deafness and Other Communication Disorders (NIDCD)
- United States Army
- Harvard University
- Hospital Italiano de Buenos Aires
- Southern Illinois University
- University of Utah
- Leiden University
- Hebrew University
- Erciyes University
- University of Tuebingen
- Fonds NutsOhra
- Strekin AG
Organization Involved with Phase 2 Indications (33)
- Novartis
- Autifony Therapeutics Limited
- Bioelectron
- GlaxoSmithKline
- Nordmark Arzneimittel GmbH & Co. KG
- Otonomy, Inc.
- Advent Health
- McGill University
- University of Florida
- University of Michigan
- University of Toronto
- University of Brasilia
- University of Colorado, Denver
- Royal National Throat, Nose and Ear Hospital
- Worldwide Clinical Trials
- Sound Pharmaceuticals
- LCR Clinical Research
- National Taiwan University
- University of Sao Paulo
- Ludwig Maximilians University
- University of Alabama, Birmingham
- Washington University in St. Louis
- Department of Veteran Affairs
- ClinSupport GmbH
- MWI Medizinisches Wirtschaftsinstitut GmbH
- Cord Blood Registry, Inc.
- ProjectPharm s.r.o.
- X-act Cologne Clinical Research GmbH
- Hearing Health Science, Inc.
- Municipal Hospital of Tainan, Taiwan
- +3 more
Organization Involved with Phase 1 Indications (13)
- Regeneron
- Pfizer
- Otologic Pharmaceutics, Inc.
- Baylor University
- Memorial Hermann Health System
- University of Oklahoma
- University of Southern California
- Metroplex Clinical Research
- Medical University of Vienna
- Wake Research Associates
- University of Texas at Houston
- MDS Pharma
- Methodist Cancer Center, Houston, Texas
Organization Involved with Other Experimental Indications (16)
- Fennec Pharma
- TRPHARM
- Chang Gung University
- Oregon Health and Science University
- Pamukkale University
- Thomas Jefferson University
- Dalin Tzu Chi General Hospital
- Fudan University
- Peking University
- Zhejiang University
- Jiao Tong University
- University of Ostrava
- Klinar CRO
- University of Antwerp
- Providence University, Taiwan
- Hospital San Juan de Dios, Santiago